INDIA BIOTECH 2024

HANDBOOK

BIOTECH
HANDBOOK
2024

Booth #4807 India

Pavilion
at BIO 2024

1
 INDIA BIOTECH 2024
HANDBOOK

2
 INDIA BIOTECH 2024
HANDBOOK

TABLE OF CONTENTS
Foreword by ABLE President  04

Overview of India’s Bioeconomy 06

India Delegation #BIO2024  21

Program Schedule  30

India Pavilion Exhibitors  32

India Exhibits at BIO San Diego 2024 Locator 62

Other Indian Exhibitors  63

India Biotech Handbook has been conceptualized & published by

Narayanan Suresh, Chief Operating Officer, Association of
Biotechnology Led Enterprises (ABLE). The editorial responsibility,
content, and analysis was co-ordinated and carried out by
Srinivas Rao Chandan, Senior Consultant to ABLE;
Ms Pavana Praveen, Manager-BDO & Ms Indrila Sengupta,
Asst. Manager-BDO.
Dr Balasubramanya S., General Manager is the Chief Coordinator
for the INDIA Pavilion@BIO San Diego, California, June 3-6, 2024;
Designed and printed by Sareeta Sajjan.

Comments & questions are welcome and should be addressed to:

Narayanan Suresh, Chief Operating Officer
 coo@ableindia.org.in  www.ableindia.in
ASSOCIATION OF BIOTECHNOLOGY LED ENTERPRISES (ABLE)
No.123/C, 16th Main Road 4th Block, 5th Cross, Koramangala,
Bangalore-560034, India. Tel.: +91-80-41636853

3
 INDIA BIOTECH 2024
HANDBOOK

Savour the
Best of India’s
Biomanufacturing
Capabilities
G S Krishnan, Hon. President - ABLE

T
he Covid pandemic highlighted the ucts across various industrial sectors. With
need for every country to have its products such as food additives, biophar-
manufacturing capabilities for vac- maceuticals, biogenic dyes, bulk chemicals,
cines, diagnostic kits, anti-virals, protec- animal feed products, flavours/fragrances,
tion kits, syringes and so on. India’s vaccine biomaterials.
manufacturing leadership came in handy
during the pandemic to deliver over 2 billion The opportunities will be huge as India’s
doses of Covid vaccines to the country and $150 billion BioEconomy that accounts for
to many parts of the world. 3.75% of the nation’s $ 4 trillion GDP chugs
along nicely in the years to come. At the core
As we prepare for the next pandemic, India of India’s thriving BioEconomy is the pres-
is embarking on an ambitious program to ence of more than 600 biotech enterprises
enhance national capabilities with an inno- and 8500+ biotech startups. A vast network
vative ‘plug and play’ model of manufac- of 200+ bioincubators and accelerators
turing for biotech products. The backbone spread across the country are aiding the
of this initiative will be the use of advanced growth of the innovative biotech ecosystem.
tools of biotech including synthetic biolo-
gy, genome editing, metabolic engineering In addition, 100+ top quality CDMOs in the
and so on. country are providing a range of services
to companies around the world with best in
As the nation prepares to roll out this initia- class bio manufacturing solutions.
tive this year, we look forward to collabora-
tions from around the world to work with In- Some of India’s top biotech companies will
dian companies and institutions to build the be present in the India Pavilion, set up the
products of tomorrow for the entire world. Association of Biotechnology Led Enterpris-
The pilot scale based biomanufacturing es (ABLE) at the BIO International Conven-
units will employ fermentation using en- tion in San Diego, from June 3-6, 2024. This
hanced microbial cell factories (and suga/ special edition of “India Biotech Handbook
biomass/waste-based raw material) and 2024” provides some glimpses into the in-
so on that are abundantly available in the stitutions and companies that are driving In-
country to manufacture bio-based prod- dia’s $150 billion BioEconomy to the targeted
ucts as an alternative to chemical prod- doubling to $300 billion by the year 2030.

4
INDIA BIOTECH 2024
HANDBOOK

5
 INDIA BIOTECH 2024
HANDBOOK

INDIA’S
BIOECONOMY
A Decade of Dazzling Growth
and Unstoppable Momentum

India’s bioeconomy has witnessed

a phenomenal rise over the past
decade, transforming from a
fledgling sector to a powerhouse
contributing significantly to the
nation’s economic growth. In
2003, India’s bioeconomy stood
at a modest $2 billion. The initial
phase witnessed steady growth,
reaching $5 billion by 2008, with
the bioeconomy tripling to $11 billion
by 2013. This period marked the
beginning of a remarkable upsurge.
From 2013 to 2018, the bioeconomy
experienced an exponential surge,
reaching a staggering $55 billion
– a phenomenal 400% growth. The
momentum continued between 2018
and 2023, with the bioeconomy
reaching a colossal $151 billion,
reflecting a robust 174% growth. This
translates to a staggering 13.7-fold
increase since 2013.
6
 INDIA BIOTECH 2024
HANDBOOK

RANKS #3
in global ethanol
production

13 MN HECTARES
world’s second-largest
cotton producer

25% VACCINES
used worldwide come
from India

670 APPROVALS
FDA-approved facilities

75 INCUBATORS
India’s active bioincubator
network

7
 INDIA BIOTECH 2024
HANDBOOK
Ethanol Cotton King Vaccine Giant: A
Powerhouse: (Almost): India staggering 25%
India ranks #3 reigns supreme as of all vaccines
in global ethanol the world’s second- used worldwide
production, largest cotton come from India!
boasting over 390 producer, with a That’s 1.25 billion
distilleries and whopping 35.5 mn doses keeping
a massive 13.8 bales and 13 mn people healthy!
billion liters of hectares dedicated
capacity! to cultivation!

Global Bioincubator
Manufacturing Boom: India’s
Leader: When bioincubator
it comes to network has
FDA-approved exploded,
facilities outside fostering
the US, India tops innovation with
with around 670 over 75 active
approvals! incubators!

8
 INDIA BIOTECH 2024
HANDBOOK

Cosmos Bio uses recombinant DNA technology for

both upstream and downstream bioprocessing. These
molecules serve as key ingredients for skin protection
and anti-aging in humans.

C
osmos Bio Pvt. Ltd. is an industrial biotech startup, manu-
facturing specialty chemicals for skin protection. Incubated
at the Centre for Cellular and Molecular Platforms (C-CAMP),
Bangalore, it currently produces two biologically active ingredi-
ents, ectoine and hyaluronic acid. Cosmos Bio uses recombinant
DNA technology for both upstream and downstream bioprocessing.
These molecules serve as key ingredients for skin protection and
anti-aging in humans. With a team comprising of protein chemists,
scientists and industry experts, Cosmos Bio aims to become a lead-
er in skin protection chemicals space.

To produce these biological ingredients for the first time in India,

the startup has been well recognized and awarded several presti-
gious government grants, including BIRAC – Biotechnology Igni-
tion Grant (BIG), and the Karnataka ELEVATE grant. Additionally,
Cosmos Bio has received many awards, including the ‘Startup of
the Year Beyond Bengaluru’ award at the Bengaluru Tech Summit
2023 from the Department of IT and BT, Government of Karnataka.

Currently, the startup is in the process of quality analysis and ob-

taining commercial licenses. The industrial-grade recombinant ec-
toine and hyaluronic acid will be available for the Indian and inter-
national markets by the end of 2024.

Cosmos Bio Pvt. Ltd.

 cosmosbiotech.com  bharat@cosmosbiotech.com

9
 INDIA BIOTECH 2024
HANDBOOK

A 13.7 FOLD
INCREASE
A Breathtaking Trajectory
From a mere $2 billion in 2003, India’s bioeconomy has ballooned to a
staggering $151 billion by 2023, reflecting a remarkable 13.7-fold increase.
This growth trajectory can be segmented into distinct phases:

Steady Growth (2003-2008): The initial years witnessed a

stable rise, with the bioeconomy reaching $5 billion by 2008,
marking a 150% increase.

Significant Acceleration (2008-2013): The next phase

saw a significant acceleration, with the bioeconomy
reaching $11 billion by 2013, a 120% growth spurt.

Exponential Surge (2013-2018): This period witnessed an

exponential surge, with the bioeconomy reaching a stag-
gering $55 billion by 2018, reflecting a phenomenal 400%
growth.

Robust Growth (2018-2023): The most

recent phase saw continued robust
growth, with the bioeconomy reach-
ing a colossal $151 billion by 2023,
marking a 174% increase.
2.2 times
increase

2.5 times
Growth

400% 173%
Growth Growth

$5 bn $11 bn $55 bn $151 bn

10 2003-2008 2008-2013 2013-2018 2018-2023
 INDIA BIOTECH 2024
HANDBOOK

Policy Measures Fueling the Bioengine

The government’s proactive policy interventions have played a
pivotal role in propelling this growth. Key measures include:
• Biofuel Policy: Introduction of biofuel policies promoting 10% and
20% blending of ethanol with petrol.
• Startup Support: BIRAC’s support for over 3,000 startups and
government-backed development of over 750 products.
• Product Linked Incentives: Schemes incentivizing the production
of pharmaceutical products within India.
• Regulatory Advancements: Formulation of globally acclaimed
Biosimilar guidelines and gene editing guidelines.
• Mission-Oriented Approach: Launching of the National BioPharma
Mission for indigenous vaccine development and the National
Medical Devices Policy 2023.
• Strategic Vision: Unveiling the National Biotechnology
Development Strategy 2020-2025, aiming for India’s recognition as
a Global Biomanufacturing Hub by 2025.

Explosive Startup Surge

A Breeding Ground for Innovation
India’s bioeconomy is not just about large-
scale figures; it’s also about fostering a
vibrant startup ecosystem. The number of
biotech startups has witnessed an 18-fold
increase from 2013 to 2023, reflecting
a staggering Compound Annual Growth
Rate (CAGR) of 33.85%. This period can be
8530
further divided into two sub-phases

Cumulative Base
of Startups
2662
462
2013 2018 2023 11
 INDIA BIOTECH 2024
HANDBOOK

Rapid Expansion Resilience and Adaptability

(2013-2018) (2019-2023)
Laying a robust Showcasing remarkable
foundation with an resilience despite global
average of 461 startups challenges, with an average
established each year. of 1174 companies established
annually.

This surge in startups highlights their dynamism and potential as

key drivers of innovation and economic growth.

BIOTECH
FUNDING SOARS
Fueling the Innovation Engine
The rise of startups is mirrored by a significant in-
crease in funding. The period 2019-2023 witnessed
a substantial rise in biotech funding deals compared
to 2014-2018. The total funding deals grew from $2.1 2014-18 2019-23
billion to $2.8 billion, with an average annual fund- $2.1 billion $2.8 billion
ing increase from $0.42 billion to $0.56 billion. This
demonstrates growing investor confidence in the
sector’s potential.

Biofuels Revolutionize BioEconomy

Biofuels have emerged as a game-chang- also saw a 3.5-fold growth in the number
er, propelling the bioeconomy for- of bioethanol refineries, along with
ward. From 2013 to 2023, the a 5.4-fold increase in produc-
average ethanol blending tion capacity. Consumption of
rate with petrol witnessed a bioethanol has also skyrock-
staggering 7.7-fold increase, eted, reflecting a remarkable
reaching 11.5%. This period 17.4-fold growth.

12
INDIA BIOTECH 2024
HANDBOOK

13
 INDIA BIOTECH 2024
HANDBOOK

GLOBAL LEADERSHIP
IN KEY BIOSECTORS
India has established itself as a global • Bt Cotton: Bt cotton production in
leader in crucial bioeconomy segments: India has witnessed a 1.6-fold increase,
• Vaccine Production: India has wit- reaching 320 million bales (2014-2024)
nessed a 4-fold increase in vaccine pro- from 200 million bales (2003-2013). This
duction capacity from 2.9 billion doses not only boosts agricultural productivity
(2003-2013) to a staggering 11.5 billion but also positions India as a significant
doses (2013-2023). This remarkable contributor to global textile production.
growth makes India a key player in global India’s bioeconomy has demonstrably
vaccine security. transformed over the past decade.
• Diagnostic Tests: The number of di-
agnostic tests conducted in India has With continued government support, a
grown by 5 times, reaching 5 billion tests thriving startup ecosystem, and a focus
(2013-2023) from 1 billion tests (2003- on innovation, India is poised to maintain
2013). This expansion strengthens In- its impressive growth trajectory and so-
dia’s capacity for early disease detection lidify its position as a global leader in the
and improved healthcare outcomes. bioeconomy.

VACCINE PRODUCTION DIAGNOSTIC TESTS BT COTTON PRODUCTION

India has witnessed a The number of diag- Bt cotton production
4-fold increase in vaccine nostic tests conducted in India has witnessed
production capacity from in India has grown by 5 a 1.6-fold increase,
2.9 billion doses (2003- times, reaching 5 billion reaching 320 million
13) to a staggering 11.5 tests (2013-23) from 1 bales (2014-24) from
billion doses (2013-23). billion tests (2003-13). 200 million bales
(2003-13).

14
INDIA BIOTECH 2024
HANDBOOK

15
 INDIA BIOTECH 2024
HANDBOOK

INDIA
Gears Up for
Biomanufacturing Boom
Aims for $300 Billion
Bioeconomy by 2030
INDIA HAS SET ITS SIGHTS ON A MONUMENTAL GOAL

A
chieving a $300 billion bio- and Prosperous India.” This nation-
economy by 2030. To propel al endeavor aims to cultivate world-
this growth, a major initia- class expertise, infrastructure, and
tive has been launched to promote a skilled workforce focused on sus-
high-performance biomanufactur- tainable manufacturing practices
ing. This initiative will foster inno- based on synthetic biology.
vation, scale-up production, and
establish robust manufacturing At the heart of this initiative lies
facilities for bio-based commercial a cutting-edge “plug and play”
products. manufacturing model designed
for Industry 4.0. The DBT envisions
This ambitious plan aligns with In- a comprehensive national infra-
dia’s rapidly growing bioeconomy structure platform that leverag-
and the vision of Green Growth es advanced biotechnologies like
outlined in the Union Budget 2023- synthetic biology, genome editing,
2024. Spearheading this initiative is and metabolic engineering to pro-
the Department of Biotechnology pel the synthetic biology capacity
(DBT) with their pioneering program of the biomanufacturing program.
titled “Fostering High Performance Central to this infrastructure are
Biomanufacturing: An Integrated biofoundries – high-throughput fa-
Approach towards Promoting Cir- cilities equipped with cutting-edge
cular Economy for Green, Clean, automation methods like robotics,

16
INDIA BIOTECH 2024
HANDBOOK

17
 INDIA BIOTECH 2024
HANDBOOK

With its potential for

innovation, energy
efficiency, and
reduced pollution,
biomanufacturing aligns
with the ethos of ‘Lifestyle
for the Environment
(LiFE)’ advocated by the
Honorable Prime Minister

AI algorithms, and high-throughput ment (LiFE)’ advocated by the Hon-

analytical equipment. orable Prime Minister. By harness-
ing biomass and waste resources,
Biofoundries play a pivotal role in a pan-India biomanufacturing
implementing a Design-Build-Test- program can cater to burgeoning
Learn (DBTL) approach, facilitating consumer demands, bolster the na-
the rapid development of tools and tion’s economy, and steer towards
datasets for rational strain improve- net-zero carbon emissions.
ment in biomanufacturing.
In light of these prospects, estab-
Pilot-scale biomanufacturing units, lishing a robust national strategy
employing fermentation with en- for advancing biomanufacturing is
hanced microbial cell factories and imperative to enhance India’s scien-
utilizing sugar, biomass, or waste- tific and economic competitiveness.
based raw materials, are envi- The proposed policy framework aims
sioned to produce a wide array of to catalyze the transition towards a
bio-based products across sectors sustainable, circular economy, driv-
like biopharmaceuticals, bulk chem- ing India’s progress towards a green-
icals, biomaterials, and more.With er and more prosperous future.
its potential for innovation, energy
efficiency, and reduced pollution,
biomanufacturing aligns with the
The nation is focusing on
ethos of ‘Lifestyle for the Environ- manufacturing.

18
 INDIA BIOTECH 2024
HANDBOOK

“BEING THERE”
a Contract Research Organisation, supporting a community of small
to medium sized companies be the best versions of themselves.

SERVICES

ABOUT TG
CDSCO, BIS, Ayush, ISO,
ASTM & ASCI Compliant

In-House Dermal & Hair

Care Testing Lab

Self-Organising & Process-

Oriented Team

FDA/EU Audited Clinical

Trial Teams

50+ Network Hospitals

CONTACT US
+91 088671 25414
care@trialguna.com
www.trialguna.com Flickr - Trial Guna

19
 INDIA BIOTECH 2024
HANDBOOK

Highlights of
BIO2023

20
 INDIA BIOTECH 2024
HANDBOOK

INDIA
Delegation
#BIO2024

21
 INDIA BIOTECH 2024
HANDBOOK

Jitendra Kumar Sanjay Saxena

Managing Director General Manager & Head (Investment)
Biotechnology Industry Research Biotechnology Industry Research
Assistance Council (BIRAC) Assistance Council (BIRAC)
 md.birac@nic.in  ssaxena.birac@gov.in

Dhiraj Kumar H.V. Darshan, IAS

Chief Manager (Technical) Managing Director
Biotechnology Industry Research Karnataka Innovation and Technology
Assistance Council (BIRAC) Society, Govt. of Karnataka
 dkumar.birac@nic.in  md.ktech@karnataka.gov.in
P M Murali
Parnika Pavanram
President, Council of Presidents;
General Manager-Biotechnology
CMD, Jananom Pvt. Ltd.
Karnataka Innovation and
Association of Biotechnology Led
Technology Society, Govt. of Karnataka
Enterprises (ABLE)
 gm2.ktech@ka.gov.in
 pmmurali@ableindia.org.in
G S Krishnan Narayanan Suresh
Hon. President COO
Association of Biotechnology Association of Biotechnology
Led Enterprises (ABLE) Led Enterprises (ABLE)
 president@ableindia.org.in  coo@ableindia.org.in

Balasubramanya S Pavana Praveen

General Manager Manager-BDO
Association of Biotechnology Association of Biotechnology
Led Enterprises (ABLE) Led Enterprises (ABLE)
 gm@ableindia.org.in  pavanapr@ableindia.org.in

Indrila Sengupta
Asst. Manager-BDO Dr. SK Samal
Association of Biotechnology Director
Led Enterprises (ABLE) Accumark Diagnostics Private Limited
 indrilas@ableindia.org.in  casamirsamal@gmail.com

Prasad Desai V L Rathi

CoFounder Chairman
ADIS Technologies Pvt. Ltd. Advanced Enzyme Technologies Ltd.
 prasad@adis.co.in  vic@specialtyenzymes.com
Michael Puls
Managing Director R&D
Advanced Enzyme Technologies Ltd.
 m.puls@evoxx.com

22
 INDIA BIOTECH 2024
HANDBOOK

Rahul Kirkinde Puneet Jaju

Associate VP-Pharma Manager, Business Development
Advanced Enzyme Technologies Ltd. Bioneeds India Pvt. Ltd.
 rahul@advancedenzymes.com  puneet@bioneeds.in
Mohamed Adil A.A SK Panigrahi
Managing Director Director
Bangalore Bioinnovation Centre (BBC) Biswa Pharmaceuticals Pvt. Ltd.
 director@bioinnovationcentre.com  suresh20in@gmail.com
Divya C Arjun Boopesh Reddy
CEO Director
BioAgile Therapeutics Pvt. Ltd. Bren Bio Park
 divya@bioagiletherapeutics.com  arjun@bren.com
Sushanth Boda Rishu Pal
Senior Director - Strategy, BD & Innovation Manager of Marketing
Biocon Biologics Bren Bio Park
 sushanth.boda@biocon.com  rishu.pal@bren.com
ALN Reddy Bheema Rao Paraselli
Vice President CEO & President
Biological E Limited Chemveda Lifesciences
 reddy.aln@biologicale.com  bheema@chemvedals.com
Martin Reers Ravi Kumar Puthukanoori
Executive Vice President VP - Technical Ops.,
Biological E Limited Dev. & Mfg. Services
 martin.reers@biologicale.com Chemveda Lifesciences
 ravikumar@chemvedals.com
Rajanikanth Rau
Sr. Vice President Piyush Chahar
Biological E Limited Director & Head, Global BD
 rajanikanth.rau@biologicale.com Chemveda Lifesciences
 piyush.chahar@chemvedals.com
N Mantena
Sr. Vice President Mansi Thumar
Biological E Limited Deputy Manager BD
 nmantena@biologicale.com Chemveda Lifesciences
 mansi.thumar@chemvedals.com
Sapna Bansi Raj
Chief Business Officer Selva Kumar Natesan
Bioneeds India Pvt. Ltd. CEO
 sapna@bioneeds.in DSK Innosciences
 selvakumar.n@dskinnosciences.com

23
 INDIA BIOTECH 2024
HANDBOOK

Rama Bhatt Sangita Sen Majee

Sr. VP-Business Development, North Head-Life Science Incubator
America IKP Knowledge Park
DSK Innosciences  sangita@ikpknowledgepark.com
 rama.b@dskinnosciences.com
Sandeep Nagesh Kondaji
Ramanan Thirumoorthy CEO, Founder
Scientific Consultant Klonec Automation Systems Pvt. Ltd.
Fermbox Bio Pvt. Ltd.  sandeep.kondaji@krishitantra.com
 info@fermbox.bio
Satish Hiremath
Rajas Warke Managing Director
Director-Molecular Biology Koncepo Scientech
HiMedia Labs. Pvt. Ltd.  satish@koncepo.com
 rajasw@himedialabs.com
Jaykumar Gowda
Radha Hariharan Chief Development Officer
Business Development Manager-North Koncepo Scientech
America (Molecular Biology)  jay@koncepo.com
HiMedia Labs. Pvt. Ltd.
 radha.h@himedialabs.com T Sarat Chandra
Lead-Business Development
Ricardo Garcia & Strategic Advisory
Business Development Manager-LatAM Koncepo Scientech
and Caribbean  sarat@koncepo.com
HiMedia Labs. Pvt. Ltd.
 rgarcia@himedialabs.com Kundan Kumar Thakur
Asst. General Manager-Business
Susant Kumar Mahapatra Development & Strategic Advisory
Hi-tech Medical College & Hospitals Koncepo Scientech
 md@3smg.in  kundan@koncepo.com
Anand Kumar Suresh Chintalapati
Managing Director Chairman & CEO
Indian Immunologicals Ltd. Mabgenex
 anandkumar@indimmune.com  suresh@mabgenex.com
Sarthak Vasudeva Aswani Valiveti
VP & Head-International Business Strategic Business Advisor
Indian Immunologicals Ltd. Mabgenex
 v.sarthak@indimmune.com  aswani.v@suchanum.com
Priyankana Mukherjee RK Panigrahi
Chief Manager & Head BioNEST Director
IKP Knowledge Park Mokshya Retails Pvt. Ltd.
 priyankana@ikpknowledgepark.com  rakesh@hi-techmedicalrkl.org

24
 INDIA BIOTECH 2024
HANDBOOK

Saral Thangam Vadiraj Gopinath

MD & CEO Managing Director
Norwich Clinical Services Vachichem International
 Saral.Thangam@norwichclinical.com  vadirajsg@vachichem.com
Tuhin Bhowmick Mahesh Bhalgat
CEO & Director CEO
Pandorum Technologies Pvt. Ltd. Veeda Clinical Research
 tuhin@pandorumtechnologies.in  mahesh.bhalgat@veedacr.com
Ajith Vaman Kamath Rajkumar Agarwal
Advisor Product Development CBO
Pandorum Technologies Pvt. Ltd. Veeda Clinical Research
 avkamath@pandorumtechnologies.in  rajkumar.Agarwal@veedacr.com
Venkatasubramanian Narayanan Sanjib Banerjee
CoFounder & CEO COO,
Peptris Technologies Pvt. Ltd. Biopharma
 venkat@peptris.com Veeda Clinical Research
 sanjib.Banerjee@veedacr.com
Udayan Sengupta
Director AK Mishra
Saurav Chemicals Ltd. Director
 udayan@sauravchemicals.com Veer Medica Pvt. Ltd.
 mailashiss@gmail.com
Sudhir Sharma
Senior Scientific Advisor Yashas Chandrashekaran
Saurav Chemicals Ltd. Director of Operations
 sudhir.sharma@sauravchemicals.com Vipragen Biosciences Pvt. Ltd.
 yashas.c@vipragen.com
Syed S Ahmed
Director & CEO Ashok Malavalli
TechInvention Lifecare Pvt. Ltd. VP Business Development,
 syed@techinvention.biz North America
Vipragen Biosciences Pvt. Ltd.
Nazneen Hamid  ashok.m@vipragen.com
Director-Corporate Affairs
TechInvention Lifecare Pvt. Ltd.
 nazneen@techinvention.biz
Jaganmohan Reddy
Founder, CEO & CSO
UR Advanced Therapeutics
 jreddy@uratpx.com

25
 INDIA BIOTECH 2024
HANDBOOK

Ganesh Vaidyanathan Shyrice Mitchell

Head of Business Development Business Development Manager
3xper Innoventure Limited Aragen Bioscience

Kshitij Rishi Raghava Reddy Kethiri

Co-founder & COO Chief Executive Officer
4basecare Aryastha Life Sciences

Dinesh Jain Laura Sailor

Founder CEO Chief Business Officer
Aagami Aryastha Life Sciences

Suresh Keshwani Subir Dubey

Global Director, In-Licensing Speciality VP, Business Development
brands and M&A Aurigene Oncology Limited
Accord Healthcare India
Sujatha Rajagopalan
Abhishek Mukhopadhyay Associate Director Business Develop-
VP & Head of Business Development ment Manager
Accord Healthcare India Aurigene Oncology Limited

Tarun Chawla Akshay Shukla

Director-Business Development Director, Business development
Adalvo Aurigene Pharmaceutical Services

Ramesh Subramanian Suhridh Sundaram

Chief Commercial Officer COO
Aragen Bioscience Avay Biosciences Pvt. Ltd.

Amar Karandikar Bharat Doshi

Sr VP Business Development Co-founder & CEO
Aragen Bioscience BioDev Services

Keshav Vasanthavada Devang Pandya

Global Head of Business Development, AGM-Business Development
Biologics Services CBCC Global Research
Aragen Bioscience
Achin Gupta
Sara Mathew CEO, One India Business
Director, Sales & Marketing Cipla
Aragen Bioscience
Jaideep Gogtay
Nitika Gupta Chief Medical Officer
Director Business Development Cipla
Aragen Bioscience

26
 INDIA BIOTECH 2024
HANDBOOK

Vijay Dahiya Brian Mulnix

VP & Head:Business Development Commercial Head, North America
Cipla Biologics
Dr. Reddys Laboratories
Nanjaraje Urs
CEO Fadi Eskandar
Clinoquent Research SVP, Head of external ecosystem collabo-
ration and partnership, Innovative assets
Bhavikkumar Patel Dr. Reddys Laboratories
Manager Business Development
COD Research Gaganjot Ahluwalia
Head - Business Development, Biologics
Manish Tandon Dr. Reddys Laboratories
Chief Financial Officer
Curadev India Mayur Sangwai
Head, Business Development and Innova-
Sourav Basu tion Licensing
Vice President Dr. Reddys Laboratories
Curadev Pharma
Navdeep Pahuja
Sourav Basu Director M&A & BD
Vice President Dr. Reddys Laboratories
Curadev Pharma
Shubhra Mehrotra
Neeraj Pant VP & Head Business Development-
Managing Director North America
DDReg Pharma Dr. Reddys Laboratories
Akshita Srivastava Shwetanuj Saha
Assistant Manager- VP-Head of Strategy, Portfolio Business
Business Development Development and Management
DDReg Pharma Systems-Biologics
Dr. Reddys Laboratories
Swadhin Sekhar Biswal
Assistant Manager-Business Aadya Malladi
Development Asst. Manager Business Development
DDReg Pharma Embio
Jayanth Shridhar Satish Nagaraj
CEO, Global Head of Biologics Head-Global Commercial Operations
Dr. Reddys Laboratories Enzene Biosciences Limited
Aditya Nadimpalli Sushil Momaya
Head-Business Development, General Manager-Biologics CDMO Sales
India Region Enzene Biosciences Limited
Dr. Reddys Laboratories
Jeyaraj Duraiswamy
Anjum Swaroop Site Head & Sr. VP, Discovery Services
Chief IP Counsel Eurofins Advinus
Dr. Reddys Laboratories 27
 INDIA BIOTECH 2024
HANDBOOK

Priya Sankaranarayan Prasant Deb

Head Business Development- Vice President
In vivo Services Jubliant Biosys
Eurofins Advinus
Mohd Saquib
Ansul Sinha Manager-Business Development
Asst. General Manager Biosimilars Jubliant Biosys
Intas Pharmaceuticals
Ripple Mehta
Ferran Garcia Director-BD and Strategic Alliance
Vice President Biosimilars, B2B Kemwell Biopharma
Intas Pharmaceuticals
Madhava Ram Paranandi
Dhairya Maheshwari Head-Process Development & MSAT
Business Head Canada Kemwell Biopharma
Intas Pharmaceuticals
Surya Prakasharao Nandam
Pathik Divate Associate Director
CEO Laurus Labs
Jehangir Clinical Development Centre
(JCDC) Abel Rajan
Head, Market Access & Branded Trade
Nilendra Singh Lupin Limited
Business Development Manager
JRF Global Anshuman Patwardhan
Sr. VP, Business Development, Biotech
Samir Pandya Lupin Limited
Global Head-Business Development
JRF Global Cyrus Karkaria
President-Biotech Division
Agunan Krishnan Lupin Limited
Director, Business Development
Jubilant Therapeutics David Monson
Executive Director,
Jay Sheth Head-Business Business Development
Development (USA - West & Canada) Lupin Limited
Jubliant Biosys
Shreyanshi Khanna
Ravichandran Sankaranarayanan Manager-Corporate Strategy & Business
Associate Director, Business Develop- Development- US Specialty & Oncology
ment Lupin Limited
Jubliant Biosys
Thomas Gillespie
Manas Verma Executive Director, Global BD
Associate Director & Head of Business Lupin Limited
Development-US
Jubliant Biosys
28
 INDIA BIOTECH 2024
HANDBOOK

Arjun Juneja Atul Raut

Chief Operating Office Vice President, Global Business
Mankind Pharma Development
Sun Pharma
Atish Majumdar
Sr President - Sales & Marketing Ayra Rachwani
Mankind Pharma Senior Manager-Global Business
Development and Licensing-
Ramesh Muthu Specialty Business
EVP-Global Business Development Sun Pharma
Mankind Pharma
Mathew Papa
Sarath Peddu Senior Director, Business Development,
Sales & Business Development North America
MSN Labs Sun Pharma
Anil Gulati Anjan Chakrabarti
Chairman & CEO VP Business Development
Pharmazz India Syngene International
Ashlesha Metkari Business Development, Jeffrey Wong
Inside Sales-North America VP & Global Head of Sales (Biologics)
Piramal Pharma Solutions Syngene International
Bala Reddy Gopal Sirasani
Founder & Director Associate Vice President
Provis Biolabs TCG Greenchem
Chirag Shah Arpit Jain
Head Clinical Operations Co-Founder
Raptim Research Limited VedTechBio Research
Pallav Patel Siddharth Shah
Chief Strategist Director-External Innovation-Asia Pacific
Redox Scientific India Zoetis
Neha Srivastava Siddharth Shah
Partner Director - External Innovation-
Remfry & Sagar Asia Pacific
Zoetis
Ramkesh Meena
CEO SK Dhakshinamoorthy
ReniassThera Pvt. Ltd. SVP & Head-IDD, Whole-time
Director
Jubilant Biosys

29
 INDIA BIOTECH 2024
HANDBOOK

PROGRAM SCHEDULE

BIO International
Convention 2024 INDIA PAVILION
June 3-6 | San Deigo, CA Inauguration in
Booth 4807
on June 3, 2024 | 3 PM
by
Dr. JITENDRA KUMAR
Managing Director
Biotechnology Industry Research
Assistance Council (BIRAC)
MR. RAKESH ADALKHA
Scan the QR Code Deputy Consul General &
to access Commercial Representative
BIO Schedule Consulate General of India
San Francisco, CA, USA
G S KRISHNAN
Hon. President - ABLE

30
 India's Leading INDIA BIOTECH
HANDBOOK
2024
IP Law Firm
Founded in 1994, K&S Partners is India's top tier Intellectual Property (IP) boutique firm, serving
clients in all areas of IP including patents, designs, trademarks, copyrights, geographical
indications, plant varieties and other related laws. With over 150+ professionals spread over
seven locations across India, we serve a large repertoire of Indian and global corporations,
including Fortune 500 companies, research institutes and universities, with a
technology-focused approach. Our affiliate Firm, J. Sagar Associates (JSA), is one of the
largest corporate commercial firms in India.

LIFE SCIENCES PRACTICE SPECIALISED EXPERTISE

Pharmaceuticals
Globally-acclaimed Chemicals
seasoned patent attorneys
Medical Devices
specialized in biotech,
chemistry and Polymers
pharmaceuticals Therapeutics
Cosmetics & FMCG
Antibody
Vaccines
Strong expertise in DNA Technology
Biodiversity law and Plant
Variety Protection law Immunotherapy
Nano-Biotech
Plant Biotechnology

Advisory Protection
Prior art searches, FTO & Litigation and contentious
infringement analysis proceedings
Landscape study and analysis Oppositions | Revocations |
Invalidity opinions OUR Infringement actions

SERVICES
WHAT WE DO Prosecution
Transactional
Due diligence in M&A Drafting, filing and
transactions; transactional prosecution of patent
support and licensing applications

Patent | Trademark | Litigation | Design | Copyright

+91 124 4708 700
Geographic Indications | Biodiversity Laws
info@knspartner.com
Digital Laws | Plant Variety | Semiconductor & Layout www.kandspartners.com
31
Our Offices: Bengaluru | Chennai | Gurugram | Hyderabad | Mumbai | New Delhi | Pune
 INDIA BIOTECH 2024
HANDBOOK

INDIA
PAVILION
EXHIBITORS

32
 INDIA BIOTECH 2024
HANDBOOK

ACCUMARK DIAGNOSTICS PRIVATE LIMITED

DIAGNOSTIC AND TREATMENT EQUIPMENT:

Accumark Diagnostics Private Limited is a healthcare organization
established in 2022 and headquartered in Bhubaneswar, Odisha, India,
specifically located at 103, Saheed Nagar. They are a group company of
Hi-Tech Medical College and Hospital, Bhubaneswar, bringing a strong
foundation to their diagnostic services.

SERVICES:
Accumark Diagnostics is dedicated to establishing a comprehensive
network of pathology and microbiology investigation units. This network will
encompass:
Fixed Pathology and Microbiology Labs: These brick-and-mortar
Accumark Diagnostics
facilities will provide a central location for patients to access a wide range

Private Limited
of diagnostic tests.
Mobile Investigation Units: Accumark aims to extend their reach through
mobile units,making diagnostic services more accessible in various
locations.

ENTREPRENEURIAL FOCUS:
The company underscores its commitment to developing and training
young entrepreneurs. This initiative empowers individuals to establish and
manage their own investigation units within the Accumark network, fostering
a spirit of self-reliance and increasing healthcare service availability across
Odisha.

MISSION AND VISION:

Accumark Diagnostics prioritizes preventative healthcare
by enabling early detection and monitoring of potential
health issues. Their mission extends beyond diagnostics,
encompassing exceptional customer service,
a comfortable testing environment, and the
delivery of accurate test results.

CONTACT:
33
FOR INQUIRIES OR APPOINTMENTS, YOU CAN REACH ACCUMARK DIAGNOSTICS PRIVATE LIMITED AT 7377292053.
 2024
INDIA BIOTECH
HANDBOOK
We develop enzymatic solutions for
chiral intermediates and more...!

Enzyme Proprietary Enzyme Library

Screening

Enzyme
Engineering

Improved
High quality targeted variants

Variants

Biocatalysis
Process
Developement

Commercial
Enzyme
Manufacturing
(Fermentors ranging from 5m3 to 60m3)

ADVANCED ENZYME TECHNOLOGIES LTD

www.advancedenzymes.com
info@advancedenzymes.com
+91-22-4170 3200
34
 INDIA BIOTECH 2024
HANDBOOK

BBC plays a crucial role in nurturing the growth of biotech

startups, accelerating the development of new biotech products
and technologies, and contributing to the overall growth of the
biotechnology ecosystem in India.

T
he Bangalore Bioinnovation Centre (BBC) is a government initiative
aimed at nurturing innovation and entrepreneurship within the bio-
technology sector. Located in Bangalore, Karnataka, often referred
to as the “Silicon Valley of India,” BBC strives to cultivate an environment
conducive to biotech innovators, startups, and researchers. Jointly estab-
lished by the Department of IT, BT and S&T, Government of Karnataka, and
the Department of Biotechnology (DBT), Government of India, BBC provides
cutting-edge infrastructure, specialized equipments, mentorship, network-
ing opportunities, and funding support to biotech startups and entrepre-
neurs. Additionally, BBC fosters collaborations among academia, industry,
and government bodies to drive innovation and commercialization in the
biotechnology sector.

BBC plays a crucial role in nurturing the growth of biotech startups, ac-
celerating the development of new biotech products and technologies, and
contributing to the overall growth of the biotechnology ecosystem in India.
The rapid growth and success of the Bangalore Bioinnovation Centre (BBC)
since its establishment in 2016 highlight its effectiveness as a hub for bio-
tech startups in India. Its strategic focus on supporting innovation across
various domains of life sciences, including Healthcare, Medtech, Pharma-
ceutical, Agriculture, food, and nutrition, Industrial biotechnology, Integrat-
ed Veterinary, Bio-IT, Bio-Electronics, Blue economy, sustainability, clean
and climate tech underscores its role in addressing critical challenges and
driving progress in these areas.

Bangalore Bioinnovation Centre (BBC)

 www.bioinnovationcentre.com  info@bioinnovationcentre.com

35
 INDIA BIOTECH 2024
HANDBOOK

With a wealth of experience and expertise we excel in conducting

trials across diverse therapeutic domains. Our strong affiliations
with multiple investigators enable us to ensure the successful
execution or trials from phase I to phase IV.

B
ioAgile Therapeutics Pvt. Ltd a distinguished clinical research or-
ganization headquartered in Bangalore, India. Our company special-
izes in delivering comprehensive end-to-end clinical research and
pharmacovigilance services to esteemed pharmaceutical, nutraceutical
and medical device industries.

With a wealth of experience and expertise we excel in conducting trials

across diverse therapeutic domains. Our strong affiliations with multiple
investigators enable us to ensure the successful execution or trials from
phase I to phase IV. We are committed to upholding the highest standards
of safety, efficacy and label claims assessment for all products involved.

In addition to our trial capabilities our services extend to encompass phar-

macovigilance activities such as case processing, signal detection, aggre-
gate reporting and regulatory compliance ensuring full adherence to in-
dustry regulations and guidelines.

With a proven track record of over 120 successfully completed studies and
the publication of 30 national and international publications, we take pride
in offering unparalleled expertise to our clients.

BioAgile Therapeutics Pvt. Ltd.

 bioagiletherapeutics.com  info@bioagiletherapeutics.com

36
INDIA BIOTECH 2024
HANDBOOK

37
 INDIA BIOTECH 2024
HANDBOOK

SAVING LIVES, IMPROVING

HEALTH AND SPREADING JOY
Biological E. Limited (BE) manufactures over 5 million doses of vaccines every day
helping prevent deadly diseases that are vaccine-preventable. BE also assists in critical
healthcare and alleviates several ailments with its pharmaceutical preparations.

 Biological E. Limited, founded in 1953, is the first private sector  Our expertise in technology transfer, process development,
biological products company in India and the first pharmaceutical and commercial manufacturing enables us to aid clients across
company in South India various stages of their journey
 Supplied more than two billion doses of vaccines for global  We offer seamless end-to-end Contract Development and
health. Leading supplier of several life-saving vaccines Manufacturing Organization (CDMO) services for biologics,
and pharmaceutical products to UNICEF, PAHO and many other covering process development to clinical and commercial GMP
global markets manufacturing of drug substances at BSL-2 and Fill-finish
 Equipped with state-of-the-art laboratories, R&D facilities,  Our aseptic fill/finish manufacturing capabilities include Liquid
and more than 5,000 highly skilled employees, including around and Lyophilized platform technology for vial, ampoule, PFS,
350 scientists cartridge, auto-injectors, and multiple drug-device combinations,
 Our facilities comply with rigorous compliance standards as well as Secondary Packaging
established by USFDA, EMEA, WHO, ANVISA Brazil, TGA Australia  We are leading in the manufacture of vaccines and
and other regulatory bodies biopharmaceuticals. Our specialty lies in in-licensing and
 Our integrated services platform encompasses Microbial, co-development, which aid us in accelerating the production of
next-generation vaccines and RNA therapeutics
CorpCom 4/2024

Conjugate, Cell Culture, mRNA, Nanotechnologies (Liposome,

Nanoparticles, Microemulsion), Peptides, Iron Colloidal, LMWH,
Emulsion & Suspension
Vaccines & Biologics | Branded Formulations | Speciality Generic Injectables
38
www.biologicale.com
 INDIA BIOTECH 2024
HANDBOOK

BIONEEDS
Preclinical Services

IND / NDA Enabling

Toxicity Studies

Discovery & Guidelines:

Exploratory Studies ICH, OECD, EMEA‑CHMP,
(Hit to Lead, LO, US‑FDA, SCHEDULE Y
in vivo Biology
models)
Impurity
Qualification
Studies

PK / TK/
Immunogenicity
Assessment

Analytical &
Bioanalytical
Services

Bioneeds is an internationally acclaimed preclinical contract research organization.

With over 16 years of expertise and cutting‑edge facilities spanning 250,000 sq. ft
& vivarium of 90+ experiment rooms, we offer tailored services to our clients
for their drug discovery & development needs. Our globally recognized certifications
include OECD GLP, AAALAC & OLAW to ensure adherence to international
standards. Our diverse portfolio covers services for Small Molecules, Generics,
Biologics, Vaccines etc.. & we support our clients for their regulatory submissions to
USFDA, EMEA, Health Canada, WHO, MHRA, ANVISA, DCGI, and RCGM,
thus making us a trusted Preclinical CRO partner."

39
 INDIA BIOTECH 2024
HANDBOOK

BISWA PHARMACEUTICALS PRIVATE LIMITED

ABOUT:
Biswa Pharmaceuticals Private Limited is a pharmaceuticals,
nutraceuticalsproducts trading and manufacturingcompany headquartered
in Bhubaneswar, India. Biswa Pharma is a group company of Hi-Tech
Medical College and Hospital, bringing a strong foundation to their
pharmaceutical, nutraceutical products supply chain.

SERVICES:
Biswa Pharma is dedicated to establishing a supply chain/ network of
pharmaceutica and nutraceutical products supply units. This network will
encompass:
Fixed Services Labs: These brick-and-mortar facilities will provide a
central location for patients to get all pharmaceutical, nutraceutical
products, services.
Mobile Investigation Units: Biswa Pharma aims to extend their reach
through mobile units, making pharmaceutical, nutraceutical products,
services more accessible in various locations.

ENTREPRENEURIAL FOCUS:
The company emboldens its commitment to developing and training young
entrepreneurs. This initiative empowers individuals to establish and manage
their own pharmaceutical, nutraceutical products supplyunits within the
Biswa Pharma network, fostering a spirit of self-reliance and increasing
pharmaceutical, nutraceutical products, service availability across different
locations of India.

MISSION AND VISION:

Biswa Pharma prioritizes pharmaceutical, nutraceutical products, services and
supporting patients to manage their health issues. Biswa Pharma’s mission
extends beyond products and services, encompassing exceptional customer
service, a comfortable service environment, and the delivery of appropriate
pharmaceutical, nutraceutical products, services.

40
INDIA BIOTECH 2024
HANDBOOK

41
 INDIA BIOTECH 2024
HANDBOOK

42
 INDIA BIOTECH 2024
HANDBOOK
Chemveda harnesses its scientific and technological expertise to
deliver full-suite Chemistry support ranging from lab-scale syn-
thesis to Process R&D, and large-scale custom development of drug
substances, key intermediates, and starting materials across multi-
ple chemistry classes.

C
hemveda Life Sciences is a leading contract research partner to the
pharmaceutical, biotechnology, agrochemical industries, and aca-
demia. As a market challenger, Chemveda is boosting its value cre-
ation along and beyond the drug discovery, development and manufactur-
ing continuum, with an emphasis on:

 Strong IP safeguarding checkpoints

 Reducing partner’s time to the market or next key R&D milestone
 Providing cost-efficiency
 Zero-conflict business models
 Being scale-agnostic chemistry focused one-stop-shop
 Solving exploration-heavy scientific problems

Chemveda harnesses its scientific and technological expertise to deliver

full-suite Chemistry support ranging from lab-scale synthesis to Process
R&D, and large-scale custom development of drug substances, key inter-
mediates, and starting materials across multiple chemistry classes. Late-
ly, we have been investing in developing in-house expertise in the most
sought-after scientific platforms to answer the existing and evolving chal-
lenges in basic and applied research.

Chemveda Life Sciences

 www.chemvedals.com  BD@chemvedals.com

43
 INDIA BIOTECH 2024
HANDBOOK

The business of the company spreads across Custom Synthesis,

Process Development and Manufacturing. The company completed
over 1100 projects during the past decade,quantities ranging from 1
mg to 1 ton, with a track record of 98% successful delivery.

D
SK InnoSciences is a growing Contract Research Organization for
Chemistry with a decade of successful operation offering services
to a wide range of global clients such as Pharmaceutical, Veteri-
nary, Agrochemical, Cosmetic, Fragrance, Polymer, Electronic, Specialty
chemicals etc. DSK’s operation is housed in a 30,000 sq. ft. building on five
acres of land in Greater Bangalore, India.

The business of the company spreads across Custom Synthesis, Process

Development and Manufacturing. The company completed over 1100 proj-
ects during the past decade,quantities ranging from 1 mg to 1 ton, with a
track record of 98% successful delivery.

The infrastructure of the Company includes 50 R&D fume hoods and a

kilo lab for manufacturing supported by a complete analytical facility
with latest instruments such as 400 MHz NMR, Prep HPLC, LCMS and
several HPLCs & GCs among many others.

With strong commitment towards employee welfare, QMS, green energy,

sustainability, environment care, women empowerment and social re-
sponsibility,this message is to invite potential clients to experience the
joy of working with DSK and become part of the list of DSK’s satisfied
customers.

DSK InnoSciences Pvt. Ltd.

 dskinnosciences.com  info@dskinnosciences.com

44
INDIA BIOTECH 2024
HANDBOOK

45
 INDIA BIOTECH 2024
HANDBOOK

46
INDIA BIOTECH 2024
HANDBOOK

47
 INDIA BIOTECH 2024
HANDBOOK

48
 2024
INDIA BIOTECH
Koncepo
HANDBOOK Scientech

International
Who We Are What We Do
• Established in 2017 | Subsidiary of • Conceptualizing and developing world-
NASDAQ listed company with a 110+ year class technical infrastructure across varied
old presence in Science & Technology sectors such as Life Science, Healthcare,
Sectors Engineering and Technological sectors, for
• Established in 2017 | Subsidiary of the well-being of future generations.
NASDAQ listed company with a 110+ year • Our expertise is to provide an integrated
old presence in Science & Technology platform for the development from
Sectors Strategic Advisory to Design and Build
• 60+ employees | 1000+ employees as a • Sector Expertise: Pharmaceuticals,
group across the world Biophar ma, Heal thcare, P etroleum/
• 50+ Customers include top 6 fortune 500 Petrochemical, Energy Generation &
companies Energy Storage, E-Mobility

Business Verticals
Strategic Advisory
Design Services
Smart Build
Technical Services
Key Achievements
USD 214 Mn Associations 15+ Clients
Business with top 10 With reputed
Investment Lifescience Educational
Advisory companies Conglomerate
5+
2+ million 7+ Advanced
Collaborations
SF Design Futuristic
Lifescience
Assignments Assignments
parks

USD 47 Mn 150+ years of

PMC-Build 15+ GMP combined
Assignments Clients experience

Clients

Koncepo Scientech International, Bengaluru, India | www.koncepo.com

49
sarat@koncepo.com / kundan@koncepo.com +918142066007 / 8297078989
 INDIA BIOTECH 2024
HANDBOOK

mAbGenEx is an antibody discovery and development company

specializing in therapeutic and diagnostic applications. Our
multifaceted approach to antibody discovery combines the
power of predictive modeling-assisted synthetic libraries and
generative AI driven protein engineering. This dual strategy
allows us to efficiently identify novel antibodies with high
specificity and affinity. At mAbGenEx, we are dedicated to
improving healthspan and lifespan through our engineered
protein solutions. Our goal is to revolutionize the field of
antibody discovery and development, offering cutting-edge
therapeutics and diagnostics that address unmet medical needs.

Our Focus
Therapeutics Diagnostics

Neglected Tropical Diseases Infectious Diseases

Infectious Diseases

Oncology

50
www.mabgenex.com bd@mabgenex.com
 INDIA BIOTECH 2024
HANDBOOK

MOKSHYA RETAILS PRIVATE LIMITED

ABOUT:
Mokshya Retails Private Limited is a health sectorsupport services company
headquartered in Bhubaneswar, India. Mokshya is a group company of
Hi-Tech Medical College and Hospital, bringing a strong foundation to their
healthcare support services.

SERVICES:
Mokshya is dedicated to establishing a comprehensive network of
healthcare support services units. This network will encompass:
Fixed Services Labs: These brick-and-mortar facilities will provide a
central location for patients to access a wide range of diagnostic tests.
Mobile Investigation Units: Mokshya aims to extend their reach through
mobile units, making healthcare equipment, aids, services more
accessible in various locations.

ENTREPRENEURIAL FOCUS:
The company emboldens its commitment to developing and training young
entrepreneurs. This initiative empowers individuals to establish and manage
their own healthcare support units within the Mokshya network, fostering a
spirit of self-reliance and increasing healthcare service availability across
different locations of India.

MISSION AND VISION:

Mokshya prioritizes healthcare support equipment, aids, services and
supporting patients to manage their health issues. Mokshya’s mission extends
beyond products and services, encompassing exceptional customer service, a
comfortable service environment, and the delivery of appropriate aids,
equipment, services.

51
 INDIA BIOTECH 2024
HANDBOOK

52
 INDIA BIOTECH 2024
HANDBOOK
We have developed a technology platform for the production
of exosomes with tuneable cargos from clinical-grade human
Mesenchymal Stem Cells, with enhanced anti-inflammatory,
anti-fibrotic, anti/pro-angiogenic, and neurogenic properties
in order to promote regeneration of different tissues.

andorum
BUILDING BLOCKS OF LIFE

P
andorum Technologies is a tissue engineering and regenerative med-
icine company that uses the foundational and translational princi-
ples of biology and engineering to design novel class therapeutic
products. Pandorum has R&D labs and clinical study centres in the US (Pan-
dorum International Inc.) and India (Pandorum Technologies Pvt. Ltd.). We
have developed a technology platform for the production of exosomes with
tuneable cargos from clinical-grade human Mesenchymal Stem Cells, with
enhanced anti-inflammatory, anti-fibrotic, anti/pro-angiogenic, and neuro-
genic properties-in order to promote regeneration of different tissues such
as, cornea (avascular), and brain, liver and lung (vascular).

Our flagship product Kuragenx - the ‘Liquid’ Cornea, integrates exosomes

carrying specialized cargos, aided by cornea-mimetic biopolymers for sus-
tained release, facilitating corneal tissue regeneration and vision resto-
ration. Studies in New Zealand rabbits, Neurotrophic Keratitis model, have
demonstrated restoration of healthy cornea with re-epithelialization, neu-
ronal plexus and stromal remodelling within three months post-treatment,
paving the way to treat patients suffering from unmet clinical needs. Ku-
ragenx has been assigned by USFDA to the Office of Tissues and Advanced
Therapies, and our First in Human clinical study is planned in 2025, to
treat advanced keratitis - a severe indication with unmet medical needs.
Kuragenx was also recently awarded orphan drug designation.

Pandorum Technologies
 www.pandorum.com  tuhin@pandorumtechnologies.in

53
 INDIA BIOTECH 2024
HANDBOOK

54
INDIA BIOTECH 2024
HANDBOOK

55
 INDIA BIOTECH 2024
HANDBOOK

DESIGNED PEPTIDE SCAFFOLDS

AS ALTERNATIVES TO ECM

De Novo CORNEA

Endo-Regenerative Corneal Implants

56
 INDIA BIOTECH 2024
HANDBOOK

Our subsidiaries, Bioneeds and Heads, provide complimentary

services that enhance Veeda’s capabilities. Bioneeds comes up
with its Pre-clinical capabilities, while Heads synergizes its
expertise in Late-stage clinical trials.

V
eeda Clinical Research Limited, a leading independent full-ser-
vice Contract Research Organization (CRO), offers comprehensive
drug development solutions from Pre-clinical to Late-stage devel-
opment. Our subsidiaries, Bioneeds and Heads, provide complimentary
services that enhance Veeda’s capabilities. Bioneeds comes up with its
Pre-clinical capabilities, while Heads synergizes its expertise in Late-
stage clinical trials. Together, Veeda gains a broader global footprint, with
trial sites in over 20+ locations, allowing for efficient drug development
services for Pharma and Biopharma companies.

Partners in creating a healthier tomorrow.

Veeda Clinical Research

 www.veedacr.com  info@veedacr.com

57
 INDIA BIOTECH 2024
HANDBOOK
Veer Medica
ORGANIZATION PROFILE
Veer Medica Private Limited is a medical equipment trading company based in Bhubaneswar,
Odisha, India incorporated on April 17th, 2017 and commencing operations on December 24th,
2023.The company aims to provide comprehensive solutions for hospitals and healthcare
facilities in the region.

OPERATIONS:
Veer Medica currently focuses on trading a wide range of medical equipment, including:

DIAGNOSTIC AND TREATMENT EQUIPMENT:

This encompasses diverse products like X-ray machines, ultrasound machines, surgical
instruments, and patient monitoring systems.

HOSPITAL FURNITURE:
The Company supplies beds, chairs, examination tables, and other furniture essential for patient
care and comfort.

HOSPITAL STATIONERY:
Veer Medica offers essential medical forms, charts, and other consumables used in daily hospital
operations.

MODULAR OPERATION THEATRES:

The Company provides prefabricated, customizable operating rooms equipped with modern
technology.

VISION AND GOALS:

Veer Medica possesses an ambitious vision for the future:

MANUFACTURING:
The Company aspires to establish its own manufacturing unit to produce high-quality medical
equipment incorporating the latest technology.

FINANCIAL GROWTH:
The Company aims to achieve a turnover of Rupees 1000 crores within the next five years,
demonstrating significant financial growth.

MARKET LEADERSHIP:
Veer Medica strives to become the leading supplier of
hospital equipment in Odisha, India, catering to the
needs of various healthcare institutions.
With a dedicated team and a clear vision for the future,
Veer Medica Private Limited is poised to make a significant
impact on the healthcare landscape in Odisha, India. Their
commitment to providing high-quality products, coupled
with their ambitious goals for manufacturing and
expansion, positions them well for continued success.

58 Veer Medica Private Limited

A/103, Saheed Nagar, Bhubaneswar - 751007.Odisha, India. Email: veermedica@gmail.com
 INDIA BIOTECH 2024
HANDBOOK

Vipragen, a globally recognized Contract Research Organization (CRO), offering end-to-

end pre-clinical services for global Pharmaceutical, Biopharmaceutical, Chemical,
Nutraceutical and Medical Device companies.

State-of-the-art laboratory with 20,000 SFT animal facility based out of Mysore.

Our team is composed of multi-disciplinary experts in Formulation development, R&D,

Pharmacology, Biology, Toxicology, Bio-analytical and DMPK areas.

Our Vivarium holds Global certi�cations like OECD GLP, AAALAC and NABL, equipped
with 21CFR Part 11 compliance systems and processes.

Our team has expertise in serving leading pharmaceutical companies in the therapeutic
areas such as Oncology, CNS, In�ammation & Autoimmune diseases, Cardiovascular
diseases, Metabolic & GI disorders, rare diseases and Neuroscience diseases as well.

We deliver scienti�cally rigorous in-depth data which are statistically signi�cant, and
100% regulatory compliant including submissions to FDA, DCGI, EMEA, OECD, and
other relevant regulatory bodies.

We ensure reliable data adhering to global standards with a focus on customer

satisfaction and offer an integrated, focused approach which is tailor made to speci�c
sponsor.

OUR SERVICES

Impurity
Discovery Regulatory
Quali cation
Services Toxicology
Studies

IND/NDA PK/TK/ Genetic Reproductive Carcinogenecity

Enabling Toxicity Immunogenicity Toxicology Toxicology Studies
Studies Assessment

YOUR TRUSTED PARTNER FOR PRE-CLINICAL SERVICES

+91 98808 04442 bd@vipragen.com 59
www.vipragen.com
 INDIA BIOTECH 2024
HANDBOOK

60
 INDIA BIOTECH 2024
HANDBOOK

Companies Stall
INDIA PAVILION EXHIBITORS

1 ABLE 4807
2 Biotechnology Industry Research Assistance Council (BIRAC) 4807-D1
3 Biocon Biologics Limited 4807-D2
4 Karnataka Innovation and Technology Society, Government of Karnataka 4807-C1
5 Hi-tech Medical College & Hospitals 4807-C2

6 Chemveda Lifesciences India Pvt. Ltd. 4807-B1

7 Biological E. Limited 4807-B2

8 Indian Immunologicals Ltd. 4807-B3

9 Bren Bio Park 4807-B4
10 Veeda Clinical Research & Bioneeds India Pvt. Ltd. 4807-A1/A2

11 Saurav Chemicals Limited 4807-A3

12 Techinvention Lifecare Pvt. Ltd. 4807-A4-I

13 Mabgenex Pvt. Ltd. 4807-A4-II

14 Advanced Enzyme Technologies Limited 4807-A5

15 IKP Knowledge Park 4807-A6

16 Koncepo Scientech International Pvt. Ltd. 4807-A7

17 Vipragen Biosciences 4807-A8-I

18 UR Advanced Therapeutics Pvt. Ltd. 4807-A8-II

19 DSK Innosciences Pvt. Ltd. 4807-A9

20 Bioagile Therapeutics 4807-A10-I

21 Vachichem International 4807-A10-II

22 Pandorum Technologies 4807-A11/12
23 Bangalore Bioinnovation Centre (BBC) 4807-A13

24 Norwich Clinical Services 4807-A14

25 HiMedia Labs. Pvt. Ltd. 61

4807-A15
 INDIA BIOTECH 2024
HANDBOOK

India Pavilion

62
 INDIA BIOTECH 2024
HANDBOOK

OTHER INDIAN
EXHIBITORS
Companies Stall
1 Ami Polymer 6051
2 Aurigene Pharmaceutical 5748
Services Limited
3 DDReg Pharma Pvt Ltd 3751
4 Dr. Reddy’s Biologics 6145
5 Jubilant Biosys Limited 4117
6 Kemwell Biopharma Pvt. Ltd. 4953
7 Premas Biotech 4251
8 Rubicon Research Pvt Ltd 3758
9 Syngene International Limited 5757

63
 INDIA BIOTECH 2024
HANDBOOK

Dr. Maneesh Paul

CEO - Microvioma Private Limited

Microvioma is a research-based Organization to reimagine life through One Health Approach.

We provide Microbiology-based solutions in several verticals contributing to the One Health
concept. Microvioma has expertise in providing solutions covering anti-infectives,
Microbiology, Molecular Biology, Pharmacology, Drug Metabolism and Pharmaco-Kinetics,
Toxicology, & Regulatory Affairs. The Founder of Microvioma, Dr. Maneesh Paul providing the
main expertise is the Lead Co-inventor and Program Director in the Discovery & Development
of Enmetazobactam - the first India-invented anti-infective to have been approved as drug by
the Global regulatory Agencies incl. EMA, UKMHRA, & USFDA.

OUR EXPERTISE OFFERINGS

Anti-infective new drug New Chemical Entity profiling in Cosmeceuticals

discovery Anti-bacterials & Anti-Fungals

Probiotics for healthy ageing Gut-Microbiome revival Microbiology Testing

OUR COLLABORATORS

MEMBER OF

Join the Community Stewardship initiative of AMRACE (AMR Action Collaborative Engagement)
“Save the existing Antibiotics”
www.microvioma.com
 Visit our Website
INDIA BIOTECH 2024
HANDBOOK

OUR STRENGTHS
• Clinical Epidemiological
research centre with ICMR
Registered Clinical Trial Centre.

EST • CDSCO Registered IEC.

• Infrastructure for Data Centric
AI enabled Research.
• DSIR Recognised Advanced
Research Laboratories with 3D
Bioprinter, Stem cell & tissue
engineering.
• Connect with Network of Aster
DM Healthcare Hospitals.
Pioneering Innovations in Assisted “To turn your dreams into reality
Reality Surgery, Microfluidics & Organ and revolutionise healthcare,
on chip disease models, Infection Connect with us.”
Control, Clinical Nutrition, Medical
image Analytics, Predictive Analytics,
Invitro diagnostics, Personalised ceobioincubator@drmoopensmc.ac.in
Medicine.

Supported By

65
 INDIA BIOTECH 2024
HANDBOOK

ABLE catalyses a symbiotic interface between the industry,

the government, academic and research institutes and
domestic and international investors.

A
ssociation of Biotechnology Led Enterprises - ABLE is a not-for-
profit pan-India forum that represents the Indian Biotechnology
Sector. It was launched in April 2003, after industry leaders felt a
need to form an exclusive forum to represent the Indian Biotechnology
Sector.

ABLE has over 400 members from all across India representing all verti-
cals of the sector like Agribiotech, Bio-pharma, Industrial biotech, Bioin-
formatics, Investment banks and Venture Capital firms, leading Research
and Academic Institutes and Law Firms and Equipment Suppliers.

The primary focus of ABLE is to accelerate the pace of growth of the Bio-
technology sector in India, through partnering with the Government in
their biotechnology initiatives to deliver optimal policies and create a
positive regulatory environment, encouraging entrepreneurship and in-
vestment in the sector, providing a platform for domestic and overseas
companies to explore collaboration and partnerships, forging stronger
links between academia and industry and showcasing the strengths of
the Indian biotech sector.

ABLE showcases India’s biotech sector through events like BioEconomy

Conclave, Voice for BT public speaking contest, brings out India BioEcon-
omy Report, BioEconomy Reports for states like Karnataka and sets up the
India Pavilion at the BIO International event in the USA annually.

Association of Biotechnology Led Enterprises

 www.ableindia.in  info@ableindia.org.in

66
INDIA BIOTECH 2024
HANDBOOK

67
Journal of Clinical Oncology, 2022,Vol
INDIA 40, Issue
2024
35, Page 4095
BIOTECH

CLINICAL BENEFIT OF CANCER DRUGS:

HANDBOOK

A REVIEW
Methods Summary
124 FDA-approved New cancer drugs
substantially reduce
Drugs the risk of death and
tumor progression, yet
255 Solid tumor only marginally extend
indications patient survival

19 Years: Meta-regression of overall survival vs. FDA indication approval sequence. Each indication’s
overall survival HR (y-axis) is mapped against the FDA approval sequence (x-axis). Initial

2003 to 2021 indication approvals are classified as 1, second indication approvals as 2, etc.

Results Introducing
E METASTASIS
TH

SP
2.8 months

ECIA
increase in OS

LISTS
(IQR, 1.97-4.60
months)

3.3 months 3 Platforms Innovations Clinical Data

increase in pfS
(IQR, 1.5-5.58 METAssay® Discovery Retrospective
months) METVivo® Repurposing Prospective
METSCAN® Prognosis
BIO USA I San Diego I A Global Biotech, headquartered in Bengaluru, India, with branches in New Jersey
and Belgium, solely focused on delaying the metastasis of primary tumors,
Jun 3 - 6, 2024 positioning novel therapies in adjuvant settings, alongside standard of care
treatment.

“Cancer cannot be cured without delaying metastasis”

For Case Studies, Visit Our Website For Partnering & Collaboration, Contact Us
68
www.mestastop.com mohan@mestastop.com